BridgeMD
New treatment option for Eyelid Dermatitis
Official title Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
ClinicalTrials.gov ID: NCT06684522
What this study is testing
What is Upadacitinib 15 MG?
Upadacitinib 15 MG is an investigational medicine, given as an once-daily treatment applied to the skin, being studied as a potential treatment for eyelid dermatitis.
Also referred to as RINVOQ.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Individuals age 18-70 years old with eyelid dermatitis for at least two months
- Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib)
- Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib.
- Willing and able participants that provide informed consent
- Willing and able participants that comply with study activities
You likely can't join if
- Self-reported history of allergic response to upadacitinib
- Subject with self-reported history of heart disease, stroke, or neurological conditions
- Currently taking topical medications for eyelid dermatitis within one week of starting study drug
- Women who are pregnant, nursing, or who may become pregnant during the study
- Non-English-speaking people
- Patients with an active serious infection
See the full eligibility criteria
- Individuals age 18-70 years old with eyelid dermatitis for at least two months
- Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib)
- Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib.
- Willing and able participants that provide informed consent
- Willing and able participants that comply with study activities
- Self-reported history of allergic response to upadacitinib
- Subject with self-reported history of heart disease, stroke, or neurological conditions
- Currently taking topical medications for eyelid dermatitis within one week of starting study drug
- Women who are pregnant, nursing, or who may become pregnant during the study
- Non-English-speaking people
- Patients with an active serious infection
- Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment.
- Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb\<8g/dL, ALC\<500 cells/mm3 and ANC \<1000 cells/mm3
- Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.
The study team makes the final eligibility decision.
Where it's taking place
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.